Black Rock Inc. Cel Sci Corp Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Cel Sci Corp stock. As of the latest transaction made, Black Rock Inc. holds 774,704 shares of CVM stock, worth $480,316. This represents 0.0% of its overall portfolio holdings.

Number of Shares

774,704

Previous 763,443 1.48%

Holding current value

$480,316

Previous $1.46 Million 38.41%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$1.11 - $1.85 $12,499 - $20,832	11,261 Added 1.48%	774,704 $898,000
Q1 2024 May 10, 2024	BUY	$1.63 - $3.08 $14,079 - $26,605	8,638 Added 1.14%	763,443 $1.46 Million
Q4 2023 Feb 13, 2024	SELL	$1.07 - $3.07 $1,246 - $3,576	-1,165 Reduced 0.15%	754,805 $2.05 Million
Q3 2023 Nov 13, 2023	BUY	$1.17 - $2.86 $2,653 - $6,486	2,268 Added 0.3%	755,970 $944,000
Q2 2023 Aug 11, 2023	BUY	$2.11 - $2.83 $35,287 - $47,328	16,724 Added 2.27%	753,702 $1.82 Million
Q1 2023 May 12, 2023	SELL	$2.17 - $3.13 $126,001 - $181,743	-58,065 Reduced 7.3%	736,978 $1.71 Million
Q4 2022 Feb 13, 2023	SELL	$1.99 - $3.52 $612,824 - $1.08 Million	-307,952 Reduced 27.92%	795,043 $1.87 Million
Q3 2022 Nov 14, 2022	SELL	$3.09 - $5.23 $154,830 - $262,059	-50,107 Reduced 4.35%	1,102,995 $3.41 Million
Q2 2022 Aug 12, 2022	SELL	$2.58 - $4.99 $4.43 Million - $8.57 Million	-1,717,769 Reduced 59.83%	1,153,102 $5.19 Million
Q1 2022 May 12, 2022	SELL	$3.93 - $7.7 $280,358 - $549,302	-71,338 Reduced 2.42%	2,870,871 $11.3 Million
Q4 2021 Feb 10, 2022	BUY	$7.1 - $12.82 $539,032 - $973,294	75,920 Added 2.65%	2,942,209 $20.9 Million
Q3 2021 Nov 09, 2021	BUY	$7.64 - $12.49 $401,130 - $655,774	52,504 Added 1.87%	2,866,289 $31.5 Million
Q2 2021 Aug 11, 2021	BUY	$8.68 - $27.49 $24.4 Million - $77.4 Million	2,813,785 New	2,813,785 $24.4 Million

Others Institutions Holding CVM

# of Institutions

Shares Held

Call Options Held

27.1K

Put Options Held

150K

View Full List

About CEL SCI CORP

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

More about CVM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account